Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy

Some human tumor lines do not form visible tumors when inoculated into immunosuppressed mice. The fate of these human tumor lines was followed by transfecting them with green fluorescence protein before inoculating them into mice. Although the tumor lines failed to grow progressively, they formed small dormant microscopic foci maintained at constant mass by balanced proliferation and apoptosis. Transfecting the cells with either VEGF165 or activated c‐Ha‐ras induced loss of dormancy, which correlated with a shift in the angiogenic balance toward increased vascularity with reduced tumor cell apoptosis. These results support a model in which loss of dormancy is controlled in part by a switch to an angiogenic phenotype. These tumor lines may serve as models for investigating the cellular mechanisms controlling dormancy and identifying those factors that promote the loss of balanced proliferation and apoptosis. Finally, these models may prove useful in the design and testing of therapies directed toward eradicating dormant tumors and preventing tumor recurrence.—Udagawa, T., Fernandez, A., Achilles, E.‐G., Folkman, J., D'Amato, R. J. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 16, 1361–1370 (2002)

[1]  H. Kleinman,et al.  Basement membrane and the SIKVAV laminin-derived peptide promote tumor growth and metastases , 1991, Cancer and Metastasis Reviews.

[2]  R. Kerbel,et al.  The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor , 2004, Angiogenesis.

[3]  J. McDonald,et al.  Occult malignant astrocytoma of pons with extracranial metastasis to bone prior to craniotomy , 2004, Acta Neuropathologica.

[4]  J. Klijn,et al.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. , 2001, The New England journal of medicine.

[5]  J. Folkman,et al.  Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.

[6]  C. Caldas,et al.  Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. , 2001, The New England journal of medicine.

[7]  R. D'Amato,et al.  Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. , 2001, Journal of the National Cancer Institute.

[8]  R. Kerbel,et al.  Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.

[9]  J. Niloff,et al.  Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  O. Brison,et al.  Regulation of FGF-3 Gene Expression in Tumorigenic and Non-tumorigenic Clones of a Human Colon Carcinoma Cell Line* , 2000, The Journal of Biological Chemistry.

[11]  O. Volpert,et al.  An in vivo function for the transforming Myc protein: elicitation of the angiogenic phenotype. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  S. R. Datta,et al.  Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. , 1999, Science.

[13]  D. Fraker,et al.  Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. , 1999, Radiology.

[14]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[15]  J. Califano,et al.  Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.

[16]  H. Matsuoka,et al.  [Disseminated carcinomatosis of the bone marrow occurring 11 years after subtotal gastrectomy for gastric cancer]. , 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[17]  J. Arbiser,et al.  p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma , 1998, Oncogene.

[18]  J. Folkman,et al.  Tumor vascularity, proliferation, and apoptosis in human melanoma micrometastases and macrometastases. , 1998, Archives of dermatology.

[19]  P. Pour,et al.  Histologic and biologic patterns of microscopic pancreatic ductal adenocarcinomas detected incidentally at autopsy , 1998, Cancer.

[20]  R. Kerbel,et al.  Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Oshika,et al.  Is xenotransplantability of human colon cancers in SCID mice affected by angiogenic factors? , 1998, Journal of the National Cancer Institute.

[22]  J. Folkman,et al.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[23]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[24]  R. Kerbel,et al.  Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. , 1996, European journal of cancer.

[25]  N. Sheibani,et al.  Repression of thrombospondin-1 expression, a natural inhibitor of angiogenesis, in polyoma middle T transformed NIH3T3 cells. , 1996, Cancer letters.

[26]  A. Multani,et al.  Non-random primary and secondary chromosomal abnormalities in human gastric cancers. , 1996, Anticancer research.

[27]  D. Hanahan,et al.  Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. , 1995, Molecular endocrinology.

[28]  R. Kerbel,et al.  Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. , 1995, Cancer research.

[29]  S. Koscielny,et al.  Re: Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[30]  Lars Holmgren,et al.  Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.

[31]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[32]  Erwin G. Van Meir,et al.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells , 1994, Nature Genetics.

[33]  R. Demicheli,et al.  Local recurrences following mastectomy: support for the concept of tumor dormancy. , 1994, Journal of the National Cancer Institute.

[34]  F Vignon,et al.  [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.

[35]  W C Black,et al.  Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. , 1993, The New England journal of medicine.

[36]  K. Kinzler,et al.  The multistep nature of cancer. , 1993, Trends in genetics : TIG.

[37]  H. Seigler,et al.  Relationship between disease-free interval and survival in patients with recurrent melanoma. , 1992, Archives of surgery.

[38]  M. L. Le Beau,et al.  A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D. Hanahan,et al.  Induction of angiogenesis during the transition from hyperplasia to neoplasia , 1989, Nature.

[40]  H. Levin,et al.  Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer , 1989, Cancer.

[41]  J. A. Andersen,et al.  Breast cancer and atypia among young and middle-aged women: a study of 110 medicolegal autopsies. , 1987, British Journal of Cancer.

[42]  K. Franssila,et al.  Occult papillary carcinoma of the thyroid. A “normal” finding in finland. A systematic autopsy study , 1985, Cancer.

[43]  Cori Bargmann,et al.  Mechanism of activation of a human oncogene , 1982, Nature.

[44]  L. Woolner,et al.  Occult papillary carcinoma of the thyroid. , 1980, Archives of surgery.

[45]  A. Billiau,et al.  Human Interferon: Mass Production in a Newly Established Cell Line, MG-63 , 1977, Antimicrobial Agents and Chemotherapy.

[46]  J. Fogh,et al.  New Human Tumor Cell Lines , 1975 .

[47]  J. Folkman,et al.  TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.

[48]  Beckwith Jb,et al.  IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. , 1963 .

[49]  J. Beckwith,et al.  IN SITU NEUROBLASTOMAS: A CONTRIBUTION TO THE NATURAL HISTORY OF NEURAL CREST TUMORS. , 1963, The American journal of pathology.

[50]  M. Batts,et al.  OSTEOGENIC SARCOMA: AN ANALYSIS OF EIGHTY CASES , 1941 .